In a paper from Schepp et al. (49), 11/181 screened patients with antibody deficiencies and unknown genetic defects with or without vascular manifestations turned out to carry two ADA2 mutations with decreased ADA2 plasma activity. The gene discussed is ADA2; the disease is agammaglobulinemia.